

Please type a plus sign (+) inside this box →



PTO/SB/08A/B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/615,329	
			Filing Date	July 8, 2003	
			First Named Inventor	HASHIMOTO, Hiromasa	
			Group Art Unit	1624	
Examiner Name	Z. TUCKER				
Sheet	1	of	3	Attorney Docket Number	223488

U.S. PATENT DOCUMENTS								
Examiner Initials ¹	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Class	Subclass	Filing Date If Appropriate
		Patent Number	Kind Code					
ZT	AA	3,644,382		Clemence et al.	12-22-1972			
ZT	AB	3,778,504		Clemence et al.	12-11-1973			
ZT	AC	4,250,317		Meyer et al.	02-10-1981			
ZT	AD	4,360,679		Meyer et al.	11-23-1982			
ZT	AE	5,280,030		Jegham et al.	01-18-1994			
ZT	AF	5,563,143		Cohan et al.	10-08-1996			
ZT	AG	5,633,388		Diana et al.	05-27-1997			
ZT	AH	5,814,651		Duplantier et al.	09-29-1998			
ZT	AI	5,998,398		Daluge et al.	12-07-1999			
ZT	AJ	6,166,219		Yamasaki et al.	12-26-2000			
ZT	AK	6,211,177		Sperl et al.	04-03-2001			
ZT	AL	6,448,281		Beaulieu et al.	09-10-2002			


FOREIGN PATENT DOCUMENTS										
Examiner Initials ¹	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Class	Subclass	Translation	
		Office	Number	Kind Code					Yes	No*
	AM	EP	0 010 063	A	CIBA Geigy AG	04-16-1980				X ⁺
ZT	AN	EP	0 507 650	A	Synthelabo	10-07-1992				X ⁺
ZT	AO	EP	0 694 535	A	Eli Lilly and Company	01-31-1996				
ZT	AP	JP	03 031264	A	Otsuka Seiyaku Kogyo KK	02-12-1991				X ⁺
ZT	AQ	JP	06-025182	A	Kanebo Ltd	02-01-1994				X ⁺
ZT	AR	WO	96/07646	A	Wellcome Foundation	03-14-1996				
ZT	AS	WO	96/35713	A	Pfizer, Inc.	11-14-1996				

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner SigNat.		Date Considered	25 SEPTEMBER 2006
------------------	--	-----------------	-------------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box → 

PTO/SB/08A/B (10-96)
Approved for use through 10/31/99. OMB 0851-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/615,329
				Filing Date	July 8, 2003
				First Named Inventor	HASHIMOTO, Hiromasa
				Group Art Unit	1624
				Examiner Name	Z. TUCKER
Sheet	2	of	3	Attorney Docket Number	223488

FOREIGN PATENT DOCUMENTS										
Examiner Initials ¹	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Class	Subclass	Translation	
		Office	Number	Kind Code					Yes	No [*]
Z	AT	WO	97/25316	A	Glaxo Group Limited	07-17-1997				
Z	AU	WO	97/41884	A	Pharma Pacific Pty.	11-13-1997				
Z	AV	WO	97/46237	A	Eli Lilly and Company	12-11-1997				
Z	AW	WO	98/05327	A	Rhône-Poulenc Rorer	02-12-1998				
Z	AX	WO	98/37072	A	U.S. Dept. Health & Human Services	08-27-1998				
Z	AY	WO	98/50029	A	Univ. of Pittsburgh	11-12-1998				
Z	AZ	WO	98/50030	A	Univ. of Pittsburgh	11-12-1998				
Z	BA	WO	98/50031	A	Univ. of Pittsburgh	11-12-1998				
Z	BB	WO	99/24060	A	Mayo Foundation	05-20-1999				
Z	BC	WO	99/51619	A	University of Michigan	10-14-1999				
Z	BD	WO	01/21634	A	Trega Biosciences, Inc.	03-29-2001				
Z	BE	WO	01/47883	A	Japan Tobacco Inc.	07-05-2001				X ⁺
Z	BF	WO	02/04425	A	Boehringer Ingelheim (Canada) Ltd.	01-17-2002				

OTHER - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials ¹	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No [*]
	BG	BEHRENS et al., <i>EMBO J.</i> , 15 (1), 12-22 (1996)		
	BH	HASKELL et al., <i>J. Med. Chem.</i> , 13 (4), 697-704 (1970)		
	BI	HORI et al., <i>Chem. Pharm. Bull.</i> , 41 (10), 1832-1841 (1993)		
	BJ	KATAEV et al., <i>Khimiko-Farmatsevticheskii Zhurnal</i> , 30 (7), 22-24 (1996)		X ⁺
	BK	KATAEV et al., <i>Pharmaceutical Chemistry Journal</i> , 30 (7), 448-450 (1996)		

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner SigNat.		Date Considered	25 SEPTEMBER 2006
------------------	---	-----------------	-------------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



PTO/SB/08A/B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/615,329
				Filing Date	July 8, 2003
				First Named Inventor	HASHIMOTO, Hiromasa
				Group Art Unit	1624
				Examiner Name	Z. TUCKER
				Attorney Docket Number	223488
Sheet	3	of	3		

[illegible]

- * A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner SigNat.		Date Considered	25 SEPTEMBER 2006
---------------------	---	--------------------	-------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box →



PTO/SB/08A/B (10-88)
Approved for use through 10/31/89. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Compleat if Kn wn

Application Number	10/615,329
Filing Date	July 8, 2003
First Named Inventor	HASHIMOTO, Hiromasa
Group Art Unit	1614-1624
Examiner Name	Z. TUCKER
Attorney Docket Number	223488

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Examiner Initials ¹	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Class	Subclass	Filing Date If Appropriate
		Patent Number	Kind Code					

FOREIGN PATENT DOCUMENTS

Examiner Initials ¹	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Class	Subclass	Translation	
		Office	Number	Kind Code					Yes	No*
Z	B0	JP	06-025182	A	Kanebo, Ltd.	02-01-1994	—	—	X	

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No*


* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature		Date Considered	25 SEPTEMBER 2006
-----------------------	--	--------------------	-------------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

+



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number	10/615,329
Filing Date	July 8, 2003
First Named Inventor	Hashimoto et al.
Group Art Unit	1614 1624
Examiner Name	Unassigned Z. TUCKER
Attorney Docket Number	223488

Sheet	1	of	1
-------	---	----	---

[illegible][illegible]


OTHER - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**

Zulh

25 SEPTEMBER 2006

- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/615,329
Filing Date	July 8, 2003
First Named Inventor	Hashimoto et al.
Group Art Unit	4614 1624
Examiner Name	Unassigned Z. TUCKER
Attorney Docket Number	223488
Client Reference No.	JF-85US-C1D1

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			
ZT	BQ	2003/0050320	A1	Hashimoto et al.	Mar. 13, 2003	
ZT	BR	2004/0082635	A1	Hashimoto et al.	Apr. 29, 2004	
ZT	BS	2004/0097438	A1	Hashimoto et al.	May 20, 2004	
ZT	BT	6,770,666	B2	Hashimoto et al.	Aug. 3, 2004	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**

Examiner Signature

[Handwritten Signature]

Date Considered

25 SEPTEMBER 2006

- * A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).